1. Home
  2. INZY vs CMT Comparison

INZY vs CMT Comparison

Compare INZY & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • CMT
  • Stock Information
  • Founded
  • INZY 2015
  • CMT 1996
  • Country
  • INZY United States
  • CMT United States
  • Employees
  • INZY N/A
  • CMT N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • CMT Electronic Components
  • Sector
  • INZY Health Care
  • CMT Consumer Discretionary
  • Exchange
  • INZY Nasdaq
  • CMT Nasdaq
  • Market Cap
  • INZY 188.2M
  • CMT 156.7M
  • IPO Year
  • INZY 2020
  • CMT N/A
  • Fundamental
  • Price
  • INZY $1.25
  • CMT $13.26
  • Analyst Decision
  • INZY Strong Buy
  • CMT Strong Buy
  • Analyst Count
  • INZY 8
  • CMT 1
  • Target Price
  • INZY $17.75
  • CMT $27.00
  • AVG Volume (30 Days)
  • INZY 677.6K
  • CMT 35.3K
  • Earning Date
  • INZY 03-11-2025
  • CMT 03-11-2025
  • Dividend Yield
  • INZY N/A
  • CMT N/A
  • EPS Growth
  • INZY N/A
  • CMT N/A
  • EPS
  • INZY N/A
  • CMT 1.75
  • Revenue
  • INZY N/A
  • CMT $313,657,000.00
  • Revenue This Year
  • INZY N/A
  • CMT N/A
  • Revenue Next Year
  • INZY N/A
  • CMT N/A
  • P/E Ratio
  • INZY N/A
  • CMT $7.60
  • Revenue Growth
  • INZY N/A
  • CMT N/A
  • 52 Week Low
  • INZY $1.24
  • CMT $13.00
  • 52 Week High
  • INZY $7.80
  • CMT $21.00
  • Technical
  • Relative Strength Index (RSI)
  • INZY 31.42
  • CMT 35.93
  • Support Level
  • INZY $1.24
  • CMT $13.00
  • Resistance Level
  • INZY $1.43
  • CMT $14.22
  • Average True Range (ATR)
  • INZY 0.10
  • CMT 0.47
  • MACD
  • INZY 0.04
  • CMT 0.00
  • Stochastic Oscillator
  • INZY 3.12
  • CMT 15.76

About INZY Inozyme Pharma Inc.

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

About CMT Core Molding Technologies Inc

Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.

Share on Social Networks: